EX-FILING FEES 6 d888593dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

Form S-4

(Form Type)

ALLOVIR, INC.

(Exact Name of Registrant as Specified in its Charter)

Table 1 - Newly Registered and Carry Forward Securities

 

                         
    

Security
Type

 

Security
Class Title

 

Fee
Calculation
or Carry
Forward
Rule

 

Amount

Registered

 

Proposed
Maximum
Offering
Price Per
Unit

   

Maximum

Aggregate

Offering Price

 

Fee Rate

 

Amount of
Registration
Fee

 

Carry
Forward

Form
Type

   

Carry

Forward

File

Number

   

Carry
Forward
Initial
effective
date

   

Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward

 
 

Newly Registered Securities

 

                         

Fees to Be

Paid

  Equity    Common 

Stock, 

$0.0001 

par value 

per share 

  Other   1,096,775(1)     (2)     3.66   $0.00015310   0.01                                
                         

Fees

Previously

Paid

  Equity    Common 

Stock, 

$0.0001 

par value 

per share 

  Other   15,927,817(1)     (2)     53.10   $0.00015310   0.01                                
 

Carry Forward Securities

 

                         

Carry

Forward

Securities

  —    —    —    —            —              —        —        —        —   
                   
    Total Offering Amounts            $56.76(2)   —    $0.02                                
                   
    Total Fees Previously Paid                    $0.18                                
                   
    Total Fee Offsets                    —                                 
                   
    Net Fee Due                    $—                                 

 

1


 

(1)

Relates to common stock, $0.0001 par value per share, of AlloVir, Inc., a Delaware corporation (“AlloVir”), issuable to holders of common stock, $0.00001 par value per share, of Kalaris Therapeutics, Inc., a Delaware corporation (“Kalaris”), in the proposed merger of Aurora Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of AlloVir, with and into Kalaris, with Kalaris surviving as a wholly owned subsidiary of AlloVir (the “merger”). The amount of common stock of AlloVir to be registered includes the estimated maximum number of shares of common stock of AlloVir that are expected to be issued (or become issuable) pursuant to the merger, assuming the conversion of certain convertible notes of Kalaris into common stock of Kalaris prior to the effective time of the merger, the conversion of other certain convertible notes of Kalaris into preferred stock of Kalaris prior to the effective time of the merger and the conversion of preferred stock of Kalaris into common stock of Kalaris prior to the effective time of the merger, and assuming an estimated exchange ratio (which is subject to adjustment prior to the closing of the merger).

 

(2)

Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the U.S. Securities Act of 1933, as amended. Kalaris is a private company, no market exists for its securities, and it has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price for the shares expected to be issued pursuant to the merger is one-third of the aggregate par value of the Kalaris securities expected to be exchanged in the proposed merger.